Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment
Authors
- Hauke S. Wülfrath (ORCID: https://orcid.org/0000-0003-2624-0726)
- Katrien Lemmens
- Maximilian T. Lobmeyer
- Wansuk Choi (ORCID: https://orcid.org/0000-0003-1324-6723)
- Nima Soleymanlou
- Silke Retlich
- Friedeborg Seitz (ORCID: https://orcid.org/0000-0002-4460-5867)
- Armin Schultz
- Atef Halabi (ORCID: https://orcid.org/0000-0001-9896-6097)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (Taiwan) (TW)
- Clinical Research Services (DE)
- University Hospital Schleswig-Holstein (DE)
- Boehringer Ingelheim (Australia) (AU)
- Boehringer Ingelheim (United States) (US)
- University of Lübeck (DE)
Publication Details
- Journal
- Expert Opinion on Investigational Drugs
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1080/13543784.2025.2510673
- Citations
- 5
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 7.15